TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

作者: Lisa M. Sedger , Michael F. McDermott

DOI: 10.1016/J.CYTOGFR.2014.07.016

关键词: InfliximabImmunologyCertolizumabGolimumabInflammationEtanerceptAdalimumabMedicineRheumatoid arthritisTumor necrosis factor alpha

摘要: Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well many normal physiological functions in homeostasis and health, anti-microbial immunity. It also appears to have central role neurobiology, although this area TNF biology only recently emerging. Here, we review the basic effector functions, discuss advantages disadvantages therapeutic neutralization - now commonplace practice treatment wide range human inflammatory diseases. With over ten years experience, an emerging anti-TNF biologics available, their modes action, which appear be far more complex than had originally been anticipated. Finally, highlight current challenges intervention TNF: (i) discover produce orally delivered small molecule TNF-inhibitors, (ii) specifically target selected producing cells or individual (diseased) tissue targets, (iii) pre-identify responders. Although future looks bright, modulation moves into era personalized medicine with society's challenging expectations durable success achieving long-term disease remission.

参考文章(357)
Sara L. Montgomery, Michael A. Mastrangelo, Diala Habib, Wade C. Narrow, Sara A. Knowlden, Terry W. Wright, William J. Bowers, Ablation of TNF-RI/RII Expression in Alzheimer's Disease Mice Leads to an Unexpected Enhancement of Pathology The American Journal of Pathology. ,vol. 179, pp. 2053- 2070 ,(2011) , 10.1016/J.AJPATH.2011.07.001
Genovese Mc, Robinson Wh, Magnano, Demyelination and inhibition of tumor necrosis factor (TNF) Clinical and Experimental Rheumatology. ,vol. 22, pp. 134- 140 ,(2004)
A. M. Bendele, L. W. Moreland, D. P. Mccabe, J. R. Caldwell, J.-M. Dayer, J. E. Seely, S. W. Martin, J. L. Frazier, S. A. Lyons, C. L. Yee, G. Henry, M. Sack, A. M. Cohen, M. E. Cosenza, C. K. Edwards, T. Kohno, M. Weisman, Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. The Journal of Rheumatology. ,vol. 27, pp. 601- 609 ,(2000)
Günther Eissner, Silvia Kirchner, Heidrun Lindner, Walter Kolch, Petra Janosch, Matthias Grell, Peter Scheurich, Reinhard Andreesen, Ernst Holler, None, Reverse Signaling Through Transmembrane TNF Confers Resistance to Lipopolysaccharide in Human Monocytes and Macrophages Journal of Immunology. ,vol. 164, pp. 6193- 6198 ,(2000) , 10.4049/JIMMUNOL.164.12.6193
J K Westwick, C Weitzel, A Minden, M Karin, D A Brenner, Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. Journal of Biological Chemistry. ,vol. 269, pp. 26396- 26401 ,(1994) , 10.1016/S0021-9258(18)47207-9
Ricky A. Sharma, William P. Steward, Andreas J. Gescher, PHARMACOKINETICS AND PHARMACODYNAMICS OF CURCUMIN Advances in Experimental Medicine and Biology. ,vol. 595, pp. 453- 470 ,(2007) , 10.1007/978-0-387-46401-5_20
P E Lipsky, D F Jelinek, Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. Journal of Immunology. ,vol. 139, pp. 2970- 2976 ,(1987)
L. R. Coulthard, J. Geiler, R. J. Mathews, L. D. Church, L. J. Dickie, D. L. Cooper, C. Wong, S. Savic, D. Bryer, M. H. Buch, P. Emery, A. W. Morgan, M. F. McDermott, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients Clinical and Experimental Immunology. ,vol. 170, pp. 36- 46 ,(2012) , 10.1111/J.1365-2249.2012.04626.X
Panagiota Stamou, Dimitris L. Kontoyiannis, Posttranscriptional regulation of TNF mRNA: a paradigm of signal-dependent mRNA utilization and its relevance to pathology. Current directions in autoimmunity. ,vol. 11, pp. 61- 79 ,(2010) , 10.1159/000289197